Revision of Precautions

Levetiracetam

January 9, 2015

Non-proprietary Name
levetiracetam

Safety measure
Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following texts should be added (underlined parts are revised):

Rhabdomyolysis:
Rhabdomyolysis may occur. Patients should be carefully monitored. If signs or symptoms including myalgia, feeling of weakness, increased creatine kinase (creatine phosphokinase), increased blood myoglobin, and increased urine myoglobin are observed, administration of this drug should be discontinued and appropriate measures should be taken.